We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1101
Fate Therapeutics
FATE
$269M
$16K ﹤0.01%
279
-47
-14% -$2.66K
MRVI icon
1102
Maravai LifeSciences
MRVI
$965M
$16K ﹤0.01%
+384
New +$15.6K
RY icon
1103
Royal Bank of Canada
RY
$290B
$16K ﹤0.01%
150
-65
-30% -$6.75K
VIR icon
1104
Vir Biotechnology
VIR
$1.45B
$16K ﹤0.01%
382
-65
-15% -$2.55K
GRCL
1105
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$15K ﹤0.01%
2,453
-2,311
-49% -$22.2K
APLS
1106
DELISTED
Apellis Pharmaceuticals
APLS
$14K ﹤0.01%
298
– –
PACB icon
1107
Pacific Biosciences
PACB
$432M
$14K ﹤0.01%
682
– –
ARVN icon
1108
Arvinas
ARVN
$527M
$13K ﹤0.01%
154
-14
-8% -$1.14K
IONS icon
1109
Ionis Pharmaceuticals
IONS
$9.09B
$13K ﹤0.01%
412
-71
-15% -$2.23K
KOD icon
1110
Kodiak Sciences
KOD
$2.43B
$13K ﹤0.01%
151
-25
-14% -$2.54K
ABCL icon
1111
AbCellera Biologics
ABCL
$1.63B
$12K ﹤0.01%
+822
New +$12.5K
ADPT icon
1112
Adaptive Biotechnologies
ADPT
$3.53B
$12K ﹤0.01%
412
-70
-15% -$2.15K
ITCI
1113
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12K ﹤0.01%
238
-41
-15% -$1.72K
NFH
1114
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$12K ﹤0.01%
1,013
– –
ACAD icon
1115
Acadia Pharmaceuticals
ACAD
$4.45B
$11K ﹤0.01%
469
-81
-15% -$1.63K
ALKS icon
1116
Alkermes
ALKS
$8.14B
$11K ﹤0.01%
472
-81
-15% -$2.13K
CYTK icon
1117
Cytokinetics
CYTK
$10.7B
$11K ﹤0.01%
245
-41
-14% -$1.58K
EDU icon
1118
New Oriental
EDU
$9.14B
$11K ﹤0.01%
520
– –
TWST icon
1119
Twist Bioscience
TWST
$5.22B
$11K ﹤0.01%
145
-24
-14% -$2.46K
ZNTL icon
1120
Zentalis Pharmaceuticals
ZNTL
$326M
$11K ﹤0.01%
132
-22
-14% -$1.7K
KRTX
1121
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$11K ﹤0.01%
86
-15
-15% -$1.94K
IVT icon
1122
InvenTrust Properties
IVT
$2.81B
$10K ﹤0.01%
+353
New +$8.91K
KYMR icon
1123
Kymera Therapeutics
KYMR
$8.68B
$10K ﹤0.01%
+150
New +$8.74K
RLAY icon
1124
Relay Therapeutics
RLAY
$3.95B
$10K ﹤0.01%
317
– –
AUPH icon
1125
Aurinia Pharmaceuticals
AUPH
$1.92B
$9K ﹤0.01%
378
-62
-14% -$1.47K
43 44
45
46 47

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.